Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer

Andrea Mancuso, Rosa Giuliani, Caterina Accettura, Marzia Palma, Giuliana D'Auria, Fabiana Cecere, Luca Paoluzzi, Mario Bezzi, Bruno Massidda, Enrico Cortesi

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background: Oxaliplatin, a new DACH-platinum compound, has provided high response rates both in untreated and 5-FU-resistant patients. Aim: to define the feasibility and toxicity profile of Oxaliplatin administered as a continuous hepatic aterial infusion. Patients and Methods: Seventeen patients with pretreated metastatic liver colorectal cancer were treated with Oxaliplatin 20 mg/m2/day by HACI x 5 days every 3 weeks. Results: Toxicity grade 3 included pain (4 out of 17), asthenia (1 out of 17) and nausea (1 out of 17). Abdominal pain grade 4 (WHO) was noted in only one patient. Overall, severe abdominal pain (main dose-limiting toxicity) was observed in 41% of patients and no chemical hepatitis and sclerosing cholangitis pain-related was proven by an endoscopic retrograde cholangiography. The response rate was not a primary end-point; nonetheless among 15 evaluable patients we observed partial responses (PR) in 7 patients (46%) and stable disease (SD) in 21% of cases for an overall tumor growth control of 67%. Progression to disease (PD) was 33%. Following chemotherapy, one patient underwent surgical removal of residual metastases, with curative intent. The 1-year survival rate was 64%. The median duration of survival was 19 months. The median delay to hepatic progression was 10 months. Conclusion: Further studies are required to define the role of HACI Oxaliplatin, the schedule of administration (bolus vs continuous infusion) and the combination, also in this setting, with fluoropyrimidines.

Original languageEnglish (US)
Pages (from-to)1917-1922
Number of pages6
JournalAnticancer Research
Volume23
Issue number2 C
StatePublished - Mar 1 2003
Externally publishedYes

Fingerprint

oxaliplatin
Colorectal Neoplasms
Neoplasm Metastasis
Liver
Abdominal Pain
Platinum Compounds
Asthenia
Pain
Sclerosing Cholangitis
Cholangiography
Liver Neoplasms

Keywords

  • Arterial infusion
  • Colorectal cancer
  • Metastatic liver
  • Oxaliplatin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mancuso, A., Giuliani, R., Accettura, C., Palma, M., D'Auria, G., Cecere, F., ... Cortesi, E. (2003). Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer. Anticancer Research, 23(2 C), 1917-1922.

Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer. / Mancuso, Andrea; Giuliani, Rosa; Accettura, Caterina; Palma, Marzia; D'Auria, Giuliana; Cecere, Fabiana; Paoluzzi, Luca; Bezzi, Mario; Massidda, Bruno; Cortesi, Enrico.

In: Anticancer Research, Vol. 23, No. 2 C, 01.03.2003, p. 1917-1922.

Research output: Contribution to journalArticle

Mancuso, A, Giuliani, R, Accettura, C, Palma, M, D'Auria, G, Cecere, F, Paoluzzi, L, Bezzi, M, Massidda, B & Cortesi, E 2003, 'Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer', Anticancer Research, vol. 23, no. 2 C, pp. 1917-1922.
Mancuso A, Giuliani R, Accettura C, Palma M, D'Auria G, Cecere F et al. Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer. Anticancer Research. 2003 Mar 1;23(2 C):1917-1922.
Mancuso, Andrea ; Giuliani, Rosa ; Accettura, Caterina ; Palma, Marzia ; D'Auria, Giuliana ; Cecere, Fabiana ; Paoluzzi, Luca ; Bezzi, Mario ; Massidda, Bruno ; Cortesi, Enrico. / Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer. In: Anticancer Research. 2003 ; Vol. 23, No. 2 C. pp. 1917-1922.
@article{2e6f0d1985794aa595132c8ddfbc6c0e,
title = "Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer",
abstract = "Background: Oxaliplatin, a new DACH-platinum compound, has provided high response rates both in untreated and 5-FU-resistant patients. Aim: to define the feasibility and toxicity profile of Oxaliplatin administered as a continuous hepatic aterial infusion. Patients and Methods: Seventeen patients with pretreated metastatic liver colorectal cancer were treated with Oxaliplatin 20 mg/m2/day by HACI x 5 days every 3 weeks. Results: Toxicity grade 3 included pain (4 out of 17), asthenia (1 out of 17) and nausea (1 out of 17). Abdominal pain grade 4 (WHO) was noted in only one patient. Overall, severe abdominal pain (main dose-limiting toxicity) was observed in 41{\%} of patients and no chemical hepatitis and sclerosing cholangitis pain-related was proven by an endoscopic retrograde cholangiography. The response rate was not a primary end-point; nonetheless among 15 evaluable patients we observed partial responses (PR) in 7 patients (46{\%}) and stable disease (SD) in 21{\%} of cases for an overall tumor growth control of 67{\%}. Progression to disease (PD) was 33{\%}. Following chemotherapy, one patient underwent surgical removal of residual metastases, with curative intent. The 1-year survival rate was 64{\%}. The median duration of survival was 19 months. The median delay to hepatic progression was 10 months. Conclusion: Further studies are required to define the role of HACI Oxaliplatin, the schedule of administration (bolus vs continuous infusion) and the combination, also in this setting, with fluoropyrimidines.",
keywords = "Arterial infusion, Colorectal cancer, Metastatic liver, Oxaliplatin",
author = "Andrea Mancuso and Rosa Giuliani and Caterina Accettura and Marzia Palma and Giuliana D'Auria and Fabiana Cecere and Luca Paoluzzi and Mario Bezzi and Bruno Massidda and Enrico Cortesi",
year = "2003",
month = "3",
day = "1",
language = "English (US)",
volume = "23",
pages = "1917--1922",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2 C",

}

TY - JOUR

T1 - Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer

AU - Mancuso, Andrea

AU - Giuliani, Rosa

AU - Accettura, Caterina

AU - Palma, Marzia

AU - D'Auria, Giuliana

AU - Cecere, Fabiana

AU - Paoluzzi, Luca

AU - Bezzi, Mario

AU - Massidda, Bruno

AU - Cortesi, Enrico

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Background: Oxaliplatin, a new DACH-platinum compound, has provided high response rates both in untreated and 5-FU-resistant patients. Aim: to define the feasibility and toxicity profile of Oxaliplatin administered as a continuous hepatic aterial infusion. Patients and Methods: Seventeen patients with pretreated metastatic liver colorectal cancer were treated with Oxaliplatin 20 mg/m2/day by HACI x 5 days every 3 weeks. Results: Toxicity grade 3 included pain (4 out of 17), asthenia (1 out of 17) and nausea (1 out of 17). Abdominal pain grade 4 (WHO) was noted in only one patient. Overall, severe abdominal pain (main dose-limiting toxicity) was observed in 41% of patients and no chemical hepatitis and sclerosing cholangitis pain-related was proven by an endoscopic retrograde cholangiography. The response rate was not a primary end-point; nonetheless among 15 evaluable patients we observed partial responses (PR) in 7 patients (46%) and stable disease (SD) in 21% of cases for an overall tumor growth control of 67%. Progression to disease (PD) was 33%. Following chemotherapy, one patient underwent surgical removal of residual metastases, with curative intent. The 1-year survival rate was 64%. The median duration of survival was 19 months. The median delay to hepatic progression was 10 months. Conclusion: Further studies are required to define the role of HACI Oxaliplatin, the schedule of administration (bolus vs continuous infusion) and the combination, also in this setting, with fluoropyrimidines.

AB - Background: Oxaliplatin, a new DACH-platinum compound, has provided high response rates both in untreated and 5-FU-resistant patients. Aim: to define the feasibility and toxicity profile of Oxaliplatin administered as a continuous hepatic aterial infusion. Patients and Methods: Seventeen patients with pretreated metastatic liver colorectal cancer were treated with Oxaliplatin 20 mg/m2/day by HACI x 5 days every 3 weeks. Results: Toxicity grade 3 included pain (4 out of 17), asthenia (1 out of 17) and nausea (1 out of 17). Abdominal pain grade 4 (WHO) was noted in only one patient. Overall, severe abdominal pain (main dose-limiting toxicity) was observed in 41% of patients and no chemical hepatitis and sclerosing cholangitis pain-related was proven by an endoscopic retrograde cholangiography. The response rate was not a primary end-point; nonetheless among 15 evaluable patients we observed partial responses (PR) in 7 patients (46%) and stable disease (SD) in 21% of cases for an overall tumor growth control of 67%. Progression to disease (PD) was 33%. Following chemotherapy, one patient underwent surgical removal of residual metastases, with curative intent. The 1-year survival rate was 64%. The median duration of survival was 19 months. The median delay to hepatic progression was 10 months. Conclusion: Further studies are required to define the role of HACI Oxaliplatin, the schedule of administration (bolus vs continuous infusion) and the combination, also in this setting, with fluoropyrimidines.

KW - Arterial infusion

KW - Colorectal cancer

KW - Metastatic liver

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=12444322664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12444322664&partnerID=8YFLogxK

M3 - Article

C2 - 12820479

AN - SCOPUS:12444322664

VL - 23

SP - 1917

EP - 1922

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 C

ER -